Loading...
CNS Pharmaceuticals, Inc.
CNSP•NASDAQ
Healthcare
Biotechnology
$8.82
$-0.12(-1.34%)
CNS Pharmaceuticals, Inc. (CNSP) Financial Performance & Statements
Review CNS Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
21.008%
↑ 21.008%
Net Income Growth
21.18%
↑ 21.18%
Operating Cash Flow Growth
-21.03%
↓ 21.03%
Operating Margin
-499832.77%
↓ 499832.77%
Gross Margin
2.13%
↑ 2.13%
Net Profit Margin
-497273.03%
↓ 497273.03%
ROE
-385.41%
↓ 385.41%
ROIC
-143.07%
↓ 143.07%
CNS Pharmaceuticals, Inc. (CNSP) Financial Statements
Explore quarterly and annual reports for CNS Pharmaceuticals, Inc. stock.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $3140.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $1570.00 | $751.00 | $752.00 |
| Gross Profit | $0.00 | $1570.00 | -$751.00 | -$752.00 |
| Gross Profit Ratio | $0.00 | $0.50 | ||
| R&D Expenses | $3.24M | $1.50M | $4.24M | $1.12M |
| SG&A Expenses | $1.09M | $1.70M | $1.38M | $1.41M |
| Operating Expenses | $4.34M | $3.20M | $5.63M | $2.53M |
| Total Costs & Expenses | $0.00 | $3.20M | $5.63M | $2.53M |
| Interest Income | $42548.00 | $26456.00 | $25230.00 | $1845.00 |
| Interest Expense | -$6208.00 | $2774.00 | $2258.00 | $4463.00 |
| Depreciation & Amortization | $0.00 | $985.00 | $751.00 | $752.00 |
| EBITDA | -$4.34M | -$3.17M | -$5.60M | -$2.53M |
| EBITDA Ratio | -$1010.38 | |||
| Operating Income | -$4.34M | -$3.20M | -$5.63M | -$2.53M |
| Operating Income Ratio | -$1019.12 | |||
| Other Income/Expenses (Net) | $36340.00 | $23682.00 | $22972.00 | -$2618.00 |
| Income Before Tax | -$4.30M | -$3.18M | -$5.61M | -$2.53M |
| Income Before Tax Ratio | -$1011.58 | |||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$4.30M | -$3.18M | -$5.61M | -$2.53M |
| Net Income Ratio | -$1011.58 | |||
| EPS | -$1.58 | -$8.31 | -$0.25 | -$52.08 |
| Diluted EPS | -$1.58 | -$8.31 | -$0.25 | -$51.90 |
| Weighted Avg Shares Outstanding | $2.73M | $22.18M | $22.18M | $48.59M |
| Weighted Avg Shares Outstanding (Diluted) | $2.73M | $22.18M | $22.18M | $48.76M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan